SEARCH

SEARCH BY CITATION

References

  • 1
    Reid IR. Menopause. In: RosenC, ed. Primer on the Metabolic Bone Diseases and Disorders of Calcium Metabolism 7th ed. Washington, DC American Society for Bone and Mineral Research 2008.
  • 2
    Russell RGG, Watts NB, Ebetino FH, Rogers MJ. Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy. Osteoporos Int. 2008; 19: 733759.
  • 3
    Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007; 356: 18091822.
  • 4
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996; 348: 15351541.
  • 5
    Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases. Mayo Clin Proc. 2006; 81: 10131022.
  • 6
    Hsu H, Lacey DL, Dunstan CR, et al. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA. 1999; 96: 35403545.
  • 7
    Fuller K, Wong B, Fox S, Choi Y, Chambers TJ. TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. 1998; 188: 9971001.
  • 8
    Lacey DL, Tan HL, Lu J, et al. Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. Am J Pathol. 2000; 157: 435448.
  • 9
    Lacey DL, Timms E, Tan HL, et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. 1998; 93: 165176.
  • 10
    Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A. 1998; 95: 35973602.
  • 11
    Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women. J Clin Endocrinol Metab. 2008; 93: 21492157.
  • 12
    Lewiecki EM, Miller PD, McClung MR, et al. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res. 2007; 22: 18321841.
  • 13
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006; 354: 821831.
  • 14
    Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008; 43: 222229.
  • 15
    Cummings SR, Martin JS, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med. 2009; 361: 756765.
  • 16
    Kendler DL, Roux C, Benhamou CL, et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2010; 25: 7281.
  • 17
    Parfitt AM, Drezner MK, Glorieux FH, et al. Bone histomorphometry: standardization of nomenclature, symbols, and units. J Bone Miner Res. 1987; 2: 595610.
  • 18
    Foldes J, Shih MS, Parfitt AM. Frequency distributions of tetracycline-based measurements: implications for the interpretation of bone formation indices in the absence of double-labeled surfaces. J Bone Miner Res. 1990; 5: 10631067.
  • 19
    Hauge E, Mosekilde L, Melsen F. Missing observations in bone histomorphometry on osteoporosis: implications and suggestions for an approach. Bone 1999; 25: 389395.
  • 20
    Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ. Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest. 1997; 100: 14751480.
  • 21
    Eriksen EF, Melsen F, Sod E, Barton I, Chines A. Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis. Bone. 2002; 31: 620625.
  • 22
    Recker RR, Weinstein RS, Chesnut CH 3rd, et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos Int. 2004; 15: 231237.
  • 23
    Recker RR, Delmas PD, Halse J, et al. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. J Bone Miner Res. 2008; 23: 616.
  • 24
    Parfitt AM. Use of bisphosphonates in the prevention of bone loss and fractures. Am J Med. 1991; 91: 42S46S.
  • 25
    Garnero P, Sornay-Rendu E, Claustrat B, Delmas PD. Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: The OFELY study. J Bone Miner Res. 2000; 15: 15261536.
  • 26
    Eastell R, Christiansen C, Grauer A, et al. Effect of denosumab on bone turnover markers in postmenopausal osteoporosis: relationship to change in bone mineral density. J Bone Miner Res. 2009; 24 (suppl 1): S475.
  • 27
    Cummings S, Yang Y-C, Vittinghoff E, et al. Increases in BMD on denosumab explain much of the reduction in fracture risk. J Bone Miner Res. 2009; 24 (suppl 1): S87.
  • 28
    Ominsky MS, Smith SY, Jolette J, Vlasseros F, Samadfam R, Kostenuik PJ. Decreased fluorochrome labeling in bone biopsies from denosumab-treated cynomolgus monkeys is related to reductions in cortical porosity and trabecular eroded surfaces. J Bone Min Res. 2009; 24 (suppl 1): S53.
  • 29
    Peterson MC, Stouch BJ, Martin SW, Miller PD, McClung MR, Fitzpatrick L. The pharmacokinetics of AMG162 following various multiple subcutaneous dosing regimens in postmenopausal women with low bone mass. J Bone Miner Res. 2005; 20 (suppl 1): S261.